Cyrocin Tablet - Uses, Side-effects, Reviews, and Precautions

                                                                    {{..CYROCIN..}}
                                                             
                                                               {..CIPROLOXACIN HCL..}

                                                                   (Film coated tablets)

COMPOSITION:
Cyrocin 250 MG Tablet is film coated tablet contents ciprofloxacin hydrochloride U.S.P…... 250 mg.
Cyrocin 500 MG Tablet is film coated tablet contents ciprofloxicin as hydrochloride U.S.P….. 500mg


Description:
Cyrocin is fluorinated 4- quinolone or antibacterial with a wider spectrum of activity then nalidixic  acid and more favourable pharmacokinetics allowed it is used is systematic infection.

Mechanism Of Action:
Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agent ciprofloxacin is a broad spectrum antibiotic that is active against both germ-positive and Gram-Negative bacteria the bacterial action of ciprofloxacin result from inhabitation of the enzymes topofisomerase ll and topoisomerase lV.which are required for bacterial DNA replication, transcription, repair and recombination.

Pharmacokinetics:
Ciprofloxacin is ready and well observed from the gastrointestinal tract oral.bioavailability is about 70 to 80% and peak plasma concentration of about 2.4 micrograms per Mol. occure 1 to 2 hour after 500 mg oral dose absorption of the ciprofloxacin  may be delayed by the presence of food, but is not substantially affected overall.
 The binding of ciprofloxacin to serum protein is 20% to 40% which is not likely to be high enough to cause significant protein binding interaction with Other Drugs.

Indications And Usage:
Cyrocin tablet is indicated for the treatment of infection caused by susceptible isolates of the designated micro-organisms in the condition and patient population listed below.



Urinary tract infection:
Cyrocin tablet is indicated in adult patients for treatment of urinary tract infection caused by Escherichia coli.

Acute uncomplicated cystitis:
Cyrocin tablet is indicated in Adult female patient for treatment of acute uncomplicated cystitis caused by  Escherichia coli.

Chronic bacterial Prostatitis:
 Cyrocin tablet is indicated in adverb patient for treatment of chronic bacterial Prostatitis caused by Escherichia coli.

Lower respiratory tract infections:
Cyrocin tablet is indicated in equal patient for treatment of lower respiratory tract infection caused by Escherichia coli cyrocin tablet is also indicated for the treatment of acute exacerbation of chronic brochititis cause by Moraxella catarrhails.

Acute sinusitis:
Cyrocin tablet is indicated in head rotation for treatment of acute Sinusitis caused by a haemophilus influenzae, streptococcus pneumoiaw.

Skin and skin structure infection:
Cyrocin tablet is indicated in adult patient for treatment of skin and skin structure infection caused by citrobactor freundii, methicillin susceptible.

                                     
                                       Dosage and administration dosage in adults:

Determination of dosage and duration for any particular patient must take into consideration the severity and nature of the infection the susceptibility of the causative microorganism the integrity of the patient host defence mechanism and the status of renal and apathetic function.

Urine specific for population: pregnancy:
Pregnancy category C because no adequate or well control study has been conduct in pragnant women.cefrofloxacin should be used during pregnancy only if the patient benefit justify the potential risk to the fetus.

Nursing mother:
ciprofloxacin is excreted in the breast milk because of the potential risk of serious adverse reaction in the infants nursing from Mother taking cyrocin a decision should be made whether to discontinue nursing or to discontinue the drug taking into account the important of the drug to the moth

Paediatric uses:
Ciprofloxacin is not a drug of first choice in the  pediatric population due to an increased incidence of adverse reaction compared to the control including event related to joint and / or surrounding tissues.

                                                  warnings and precautions

The following precaution and warning should be measured during cyrocin treatment are

Fluoroqinolone Including ciprofloxacin have neuromuscular blocking activity and m.ay exacerbate muscle weakness in person with myasthenia gravis.ciprofloxacin in patient with
known history of myasthenia gravis.


                                                                                                               Manufactured by:
                                                                                                                  Titlis Pharma
                                                                                                                for
                                                                                                                  Highnoon  Laboratories Ltd

                                                                                                  

Read More

Pregnancy while taking progyluton | Trying to Conceive & Women's

                                                          {{..PROGYLUTON..}}

                                     (ESTRADIOL VALERATE NORGESTRAL)

                                                                    TABLETS

NAME OF THE MEDICINAL PRODUCT:

PROGYLUTON


QUALITATIVE AND QUANTITATIVE COMPOSITION:
Each white sugar-coated tablet contain estradiol valerate 2.0 mg
Each light brown sugar-coated tablet contain estradiol valerate 2.0 mg and nosrgestral 0.5 mg

                                           
                    

                                              CLINICAL PARTICULARS

INDICATION (S)
Hormone replacement therapy for the treatment of signs and symptoms of estrogen deficiency due to neutral menopause or  hypogonadism Castration or primary ovarian failure in women with an intact uterus Prevention of postmenopausal osteoporosis.Control of irregular menstrual cycles treatment of primary or secondary amenorrhea.


                                                       DOSAGE REGIMEN

HOW TO START PROGYLUTON:

If the patient is in minus protein treatment should begin on the 5th day of the cycle first day of menstrual bleeding equal to first day of the cycle patient with amenorrhea  or very infrequent period or who are postmenopausal may start at anytime provided pregnancy has been excluded.

DOSAGE:
1 white tablet is taken daily for the first 11 days followed by 1 light brown tablet daily for 10 days.
 Following the 21 days of tablet taking there will be a tablet free interval of 7 days

ADMINISTRATION:
Each pack covers 21 days of treatment.A new pack of progyluton should be started after the seven days Tablet free interval on the same day of the week as the previous one.The tablets are  be swallowed whole with some liquid the tablet should preferably be taken at the same time everyday.

MISSED TABLETS:
In case a tablet is forgotten, it should be taken as soon as possible if more than 24 hours have elapsed no extra tablet need to be taken if several tablet are forgotten bleeding may occur bleeding usually occur during the tablet free interval of 7 days within a few days after the last tablet was taken

         
                {{..ADDITIONAL INFORMATION ON A SPECIAL POPULATIONS..}}


                                             CHILDREN AND ADOLESCENTS

Progyluton is not indicated for use in children and adolescents

GERIATRIC PATIENTS:
There are no data suggesting a need for dosage adjustment in elderly patients in women aged 65 years or older see-section special warnings and precautions for use


PATIENT WITH RENAL IMPAIRMENT:
Progyluton has not been specifically studied in patient with hepatic impairment. Progyluton is contraindicated  in women with severe hepatic diseases.

PATIENT WITH RENAL IMPAIRMENT:
Progyluton have not been specifically studied in renally impaired patients available data do not suggest a need for Dosage adjustment in this patient population.


SPECIAL WARNING AND PRECAUTION FOR USE:
Before initiating therapy all conditions/risk factor mentioned below should be considered when determining the individual benefit/ risk of treatment for the patient during HRT use therapy should be discontinued immediately in case a contraindication is discovered heavy rain in the following situation.Migrainous frequent and unusually severe headache is that accur for the first time or other symptoms that are possible for prodroma of cerebrovascular occlusion.Recurrence of cholestatic jaundice or cholestatics pruprite which occurred first during pregnancy or previous of sex steroid.


PREGNANCY AND LACTATION:
HRT is not indicated for use during pregnancy or lactation.if pregnancy occur during medication with progyluton treatment should be discontinued immediately small amount of sex hormones may be excreted in human milk.
 .

                                        CHILDREN AND ADOLESCENTS

                                    Progyluton is not indicated for use in children and adolescents.

GERIATRIC PATIENTS:
There are no data suggesting a need for dosage adjustment in elderly patients in women aged 65 years or older see-section special warnings and precautions for use.

PATEINT WITH HEPATIC  IMPAIRMENT:
Progyluton has not been specifically studied in patient with hepatic impairment. Progyluton is contraindicated  in women with severe hepatic diseases.

PATIENT WITH RENAL IMPAIRMENT:
Progyluton have not been specifically studied in renally impaired patients available data do not suggest a need for Dosage adjustment in this patient population.

                                SPECIAL WARNING AND PRECAUTION FOR USE

Before initiating therapy all conditions/risk factor mentioned below should be considered when determining the individual benefit/ risk of treatment for the patient during HRT use therapy should be discontinued immediately in case a contraindication is discovered heavy rain in the following situation.Migrainous frequent and unusually severe headache is that accur for the first time or other symptoms that are possible for prodroma of cerebrovascular occlusion.Recurrence of cholestatic jaundice or cholestatics pruprite which occurred first during pregnancy or previous of sex steroid.



                                              PREGNANCY AND LACTATION

HRT is not indicated for use during pregnancy or lactation.if pregnancy occur during medication with progyluton treatment should be discontinued immediately small amount of sex hormones may be excreted in human milk.

                                            PHARMACOLOGICAL PROPERTIES

PRECLINICAL SAFETY DATA:
The result from toxicity with repeated administration including tumorigenicity studies with the two active substances are not suggest of a particular risk related to use in human however, it has to be Born in mind that sex sreriod can promote the growth of certain hormone dependent tissues and tumor.
 .



MANUFACTURED BY:

BAYER WEIMAR GMBH AND CO.KG, WEIMAR                                                                                                      GERMANY

                                                                                          

Read More

Anti-Allergy Medication Tablet Uses

                                                                   {{ ..XADINE..}}

                                                        (FEXOFENADINE HCL USP)

                                                                       TABLETS

                                                                  DESCRIPTION:

FEXIFENADINE HYDROCHLORIDE:
USP the active ingredient of xadine is histamine H1.Receptor antagonist with the chemical name.
The molecular weight is 538.13 and empirical formula is C32, H39 N04 HCL.


                                                          COMPOSITION:

XADINE 60 MG TABLETS:
Each film coated tablet contain 60mg fexofenadine hydrochloride USP as actve ingredient.
120mg fexofenadine hydrochloride USP as actve ingredient.
180mg fexofenadine hydrochloride USP as actve ingredient.




                                                   CLINICAL PHARMACOLOGY:


MECHANISM OF ACTION:
 Fexofenadine a metabolite of terfenadine is an antiìstanine with selective peripheral  H1.  Recepotor antagoist activity. Fexofenadine antigen-induced bronchospasm and histamine release from peritoneal mast cells. No anticho5inergic or alpha 1.
Adregenic receptor blocking effects was abserved. Moreover, no sedative or other central nervous system efects were abserved. Fexofenatine does not cross the blood-brain barrier


PHARMACOKINETICS:
Fexofenadine hydrochloride was rapdily absorbed with a mean time to maximum  plasma concentration occuring at 2.6 hours post dose. Althrough the absolute bioavailability of fexofenadine hydrochloride tablet is unknown. Thetablet is bioequitalent to an oral solution. The mean elimination half-life of fexofenadine was  14.4 hours of 60 mg twice daily.



                                                      SPECIAL POPULATION:


Special population pharmacokinetics obtaine after a single doso of 80 mg. These special population patients were subtantielly older. Thus an age effect may be confounding the pharmacokinetic differences observed in some of the special populations.


                                                             EFFECT OF AGE:


In older subjects (> 65 years old) peak plasma levels of bexofenadine were 99 % greater than thore (< 65 years old) mean elimination half-lives were simillar to those  observed in normal.


HEPATICALLY IMPAIRED:
Across reveral trials,no clinicaly significant gender-realated differences where observerd in the pharmacokinetics of fexofenadiine.

                                                             PHARMACODYNAMICS:



WHEAL AND FLARE:
Human histamine skine weal and flare studies following single and twice daily doses of 20 mg and 40 mg fexofenadine demostrated that the drug exhibits an antihistamine effect by 1 hour, achieves maximum effect at 2-3 hours and an effect is still seen at 12 hourse. There was no evidence of tolerance to these effects after 28 days of dosing.


                                                                  INDICATIONS:

XADINE 60 MG AND XADINE 120 MG.:
Xadin 60 mg tablet/xadine 120 mg tablet is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adualts and children 12 year of age and older. Symptoms treated effectively include sneezing, rhinorrhea, itchy nose /palate / throat /itchy /watery /red eyes.



XADINE 180 MG TABLETS:
Xadine 180 mg tablets is indicated for the relief of symptoms associated with chronic idiopathic urticaria.                        


                                                       PREGNANCY:

TERATOGENIC EFFECTS:
Category c. There are no adeguate and well controlled studies in pregnant women. Fexofenadine should be used during pregnancy only it the potential benefit justifies the poptential risk to the fetus



                                                        INSTRUCTIONS:
TO BE SOLD ON PRESCRIPTION OF A REGISTERED MEDICAL PRACTITIONER ONLY.
PROTECT FROM MOISTURE,FREEZING, EXCESSIVE HEAT AND SUNLIGHT

.

                              {{-- KEEP OUT OF THE REACH OF CHILDREN--}}

                                                                                                                             MFG:

                                                                                                                          USP Spec

                                                                                                                   MANUFACTURED BY :

                                                                                                                   THE SEARLE COMPANY

                                                                                                                                   LIMITED

                                                                                                                     

Read More

PURPAL (ESOMAPRAZOLE ) ///// CAPSULES USES

                             
                                              {{..PURPAL..}}

                             [ESOMEPRAZOLE MAGNESIUM]

                                                 [CAPSULE]

                           

COMPOSITION: Purpal 40 mg:    Each capsule equaivalent to Esomeprazole 40 mg

               purple 20 mg:    Each capsule equaivalent to Esomeprazole 20 mg

                                                           
                                                                 


PHARMACOLOGICAL CLASSIFICATION: Proton pump inhibitor






DESCRIPTION:
The active ingredients in puple /DELAYED RELEASE CAPSULE/ is bis [(S)-[(4-methoxy-3, 5-dimethyle-2-pyridinyl)
     




1 CLINICAL PHARMACOLOGY:

ABSORPTION:
purple delayed release capsules contain in enteric-coated pellet formulation of esomeprazole.so that absorption of esomaprazole begins only after the granules leave the stomach.After oral administration, peak plasma levels occure at approximately 1.5 houres.The increase proportionally when the dose is increased and there is a three fold increase in the area under the plasma concentration time corve from 20 40 mg.

       

DISTRIBUTION PURPAL:    
Distribution purpal is 97% bound to plasma protiens.Plasma orotien binding over the  concentration range 2 to 20 mol/L.The apparent volum of distribution at steady state in healthy volunteers is approximatly 16L.

     
     

EXCRETION:
The plasma elimination half-life of purpal is approximatlly 1.5 hours.Less then 1 % of parent drugs is excreted in the urine. Approximatelly 80 % of an oral dose of pupale is excreted  is inactive metabolites in the urine and the remainder is found as inactive metabolites
in the faces,


 .

2 PHARMACODYNAMICS:


MECHANISM OF ACTION:
Esomeprazole is a proton  pump inhibitor that suppress gastric acid secretion by specific inhibition of the  H/K-ATPASE in the gastric parietal cell. The  S and R isomers of omeprazole are protonated and converted in the acidic compartment of the parietal cell forming the active inhibitor the achiral sulphenamide. By acting specifically on the proton punp.Eromeprazole blocks the final step in acidic production thus reducing gastric acidity.





3 INDICATIONS AND USAGE



HEALING OF EROSIVE ESOPHAGITIS: Purpal is indicated for the short-time treatment (4 to 8 weeks) in healing and symptomatic resolution of  diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 weeks course of purpal may be considered

        .

HEARTBURN AND OTHER SYMPTOMS:
Pupal delayed release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD
        .

MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS:
Purpal delayed release capsules are indicated to maintain symptoms resolution andhealing of erosive esophagitis. Controlled studies do no extend beyond  6 months
.

CONTRAINDICATIONS:
Purpal  capsules are contraindicated in patients with know                                                                        hypersensitivity to any component of the formulation.







                                                                  WARNINGS:




CLARITHROMYCIN: it should not be use in pregnant women except in clinical circumstances where no alternative therapy is appropriate If pregnancy occurs while taking clarithromycin. The patient should be apprised of the potential hazard to the fetus..
     

AMOXICILLIN:
Serious and occasionally fatal hypersensitivity reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur  in individuals with a history of penicillin hypersensitivity and/or a  history of sensitivity to multiple allergens.
                           
                                           

MANUFACTURED BY:
DYSON RESEARCH              
                                                                                                     LABORATORIES (PVT.)LTD
ISO 9001:2000 CERTIFIED
                                                                                                        COMPANY

                                                                                   

                                                                                          

Read More